EVOPRESS Injection

EVOPRESS Injection is a Vasopressin I.P. formulation designed for use in hospital and critical-care settings where vasopressor therapy is required. Vasopressin is a potent peptide hormone that produces vasoconstrictive effects through vascular V1 receptors and can help increase systemic vascular resistance and mean arterial blood pressure.

The injectable is primarily relevant to the management of vasodilatory shock in adults who remain hypotensive despite appropriate fluid resuscitation and catecholamine therapy. Its clinical application includes selected cases of septic shock and post-cardiotomy vasodilatory shock where additional vasopressor support is required.

EVOPRESS Injection contains 20 Units of Vasopressin per 1 mL and is supplied as a 5 × 1 mL ampoule presentation. The product is intended for professional use in controlled healthcare environments where blood pressure, cardiac function and other haemodynamic parameters can be appropriately monitored.

Vasopressin provides a distinct mechanism of vasoconstriction compared with catecholamine-based vasopressors. Its activity at vascular V1 receptors promotes contraction of vascular smooth muscle, supporting vascular tone and blood pressure in appropriately selected patients.

For pharmaceutical distributors, hospital procurement teams and institutional healthcare suppliers, EVOPRESS Injection represents a specialized cardiovascular and critical-care injectable for hospital-based vasopressor requirements. It may be relevant to intensive care units, emergency departments, critical-care facilities and other institutional settings managing patients with severe circulatory instability.

EVOPRESS should be administered only by qualified healthcare professionals and according to approved prescribing information and institutional critical-care protocols. Appropriate haemodynamic monitoring is important during therapy because vasopressin can affect cardiac output, heart rate and peripheral or visceral perfusion.